Coliseum Capital Management Decreased Bioscrip (BIOS) Holding as Stock Value Rose; As Facebook (FB) Share Value Rose, Shareholder Dixon Hubard Feinour & Brown Has Trimmed Position

January 13, 2018 - By Nellie Frank

Christopher Shackelton decreased its stake in Bioscrip Inc (BIOS) by 66.4% based on its latest 2017Q3 regulatory filing with the SEC. Coliseum Capital Management Llc sold 3.73 million shares as the company’s stock rose 8.97% with the market. The hedge fund run by Christopher Shackelton held 1.89M shares of the health care company at the end of 2017Q3, valued at $5.20 million, down from 5.62 million at the end of the previous reported quarter. Coliseum Capital Management Llc who had been investing in Bioscrip Inc for a number of months, seems to be less bullish one the $382.55 million market cap company. The stock decreased 5.66% or $0.18 during the last trading session, reaching $3. About 4.32 million shares traded or 306.14% up from the average. BioScrip, Inc. (NASDAQ:BIOS) has declined 29.17% since January 13, 2017 and is downtrending. It has underperformed by 45.87% the S&P500.

Dixon Hubard Feinour & Brown Inc decreased its stake in Facebook Inc (FB) by 3.55% based on its latest 2017Q3 regulatory filing with the SEC. Dixon Hubard Feinour & Brown Inc sold 2,020 shares as the company’s stock rose 10.88% with the market. The institutional investor held 54,875 shares of the technology company at the end of 2017Q3, valued at $9.38M, down from 56,895 at the end of the previous reported quarter. Dixon Hubard Feinour & Brown Inc who had been investing in Facebook Inc for a number of months, seems to be less bullish one the $521.22B market cap company. The stock decreased 4.47% or $8.4 during the last trading session, reaching $179.37. About 77.55 million shares traded or 357.64% up from the average. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since January 13, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Since August 7, 2017, it had 0 insider purchases, and 38 selling transactions for $950.72 million activity. Cox Christopher K sold $2.73M worth of stock. Stretch Colin sold $131,470 worth of stock. Another trade for 37,963 shares valued at $6.53 million was sold by Schroepfer Michael Todd. 640,754 shares were sold by Koum Jan, worth $109.70 million. The insider Zuckerberg Mark sold $42.50M. FISCHER DAVID B. also sold $806,019 worth of Facebook, Inc. (NASDAQ:FB) on Thursday, October 26.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on February, 7. They expect $1.94 EPS, up 56.45% or $0.70 from last year’s $1.24 per share. FB’s profit will be $5.64B for 23.11 P/E if the $1.94 EPS becomes a reality. After $1.59 actual EPS reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts 22.01% EPS growth.

Among 53 analysts covering Facebook (NASDAQ:FB), 49 have Buy rating, 2 Sell and 2 Hold. Therefore 92% are positive. Facebook had 217 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 2 by Citigroup. Pacific Crest reinitiated Facebook, Inc. (NASDAQ:FB) on Friday, January 20 with “Overweight” rating. As per Thursday, July 30, the company rating was maintained by Deutsche Bank. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, August 18. The firm has “Overweight” rating by Piper Jaffray given on Thursday, January 28. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, November 2. The rating was maintained by Credit Suisse with “Outperform” on Friday, October 9. The stock has “Buy” rating by Stifel Nicolaus on Thursday, January 28. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Friday, July 14 by Cowen & Co. The rating was maintained by Citigroup on Friday, April 1 with “Buy”.

Investors sentiment decreased to 1.15 in 2017 Q3. Its down 0.25, from 1.4 in 2017Q2. It dropped, as 53 investors sold FB shares while 618 reduced holdings. 128 funds opened positions while 644 raised stakes. 1.63 billion shares or 0.88% more from 1.62 billion shares in 2017Q2 were reported. At Bancshares accumulated 4,011 shares. Virginia Retirement Sys Et Al holds 1.67% or 804,900 shares in its portfolio. Meritage Portfolio holds 56,738 shares. Rfg Advisory Grp Limited Com reported 9,196 shares. Scge Limited Partnership accumulated 300,000 shares. Falcon Point Cap Limited Co reported 0.03% in Facebook, Inc. (NASDAQ:FB). Dana Advsrs holds 1.72% or 218,303 shares. Hamilton Lane Ltd Liability holds 101,773 shares. Deroy And Devereaux Private Invest Counsel holds 1,920 shares or 0.04% of its portfolio. Scharf Investments Lc stated it has 7,805 shares. Ashford Mgmt reported 8,630 shares or 0.24% of all its holdings. Aldebaran Financial accumulated 21,661 shares or 2.55% of the stock. Convergence Investment Partners Limited Liability Company has 25,059 shares for 0.61% of their portfolio. Capital Mgmt Ny holds 2,527 shares. D E Shaw And invested in 1.90 million shares or 0.5% of the stock.

Analysts await BioScrip, Inc. (NASDAQ:BIOS) to report earnings on March, 2. They expect $-0.08 EPS, 0.00% or $0.00 from last year’s $-0.08 per share. After $-0.12 actual EPS reported by BioScrip, Inc. for the previous quarter, Wall Street now forecasts -33.33% EPS growth.

Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.21, from 1.26 in 2017Q2. It dived, as 11 investors sold BIOS shares while 32 reduced holdings. 17 funds opened positions while 28 raised stakes. 104.38 million shares or 0.59% more from 103.77 million shares in 2017Q2 were reported. Natixis has invested 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS). Menta Ltd Liability Corporation holds 0.1% or 244,264 shares. Deerfield Communication has 1.11M shares. Sei Commerce holds 0% of its portfolio in BioScrip, Inc. (NASDAQ:BIOS) for 23 shares. Invesco reported 344,795 shares. State Street accumulated 1.82 million shares or 0% of the stock. Ameritas Inv accumulated 0% or 9,711 shares. 280,320 were accumulated by Amundi Pioneer Asset. Advisory Limited Liability Corporation holds 19,200 shares. Diamond Hill Capital Mgmt holds 0.06% or 3.80M shares in its portfolio. Goldman Sachs Gru has invested 0% in BioScrip, Inc. (NASDAQ:BIOS). Credit Suisse Ag has 0% invested in BioScrip, Inc. (NASDAQ:BIOS). Benjamin F Edwards And stated it has 0% in BioScrip, Inc. (NASDAQ:BIOS). Barclays Pcl reported 2,896 shares. Nationwide Fund Advsr, a Pennsylvania-based fund reported 62,115 shares.

Among 6 analysts covering BioScrip (NASDAQ:BIOS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioScrip had 13 analyst reports since August 11, 2015 according to SRatingsIntel. On Tuesday, July 25 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by SunTrust on Wednesday, December 20 with “Buy”. The firm has “Buy” rating given on Thursday, November 2 by Jefferies. SunTrust downgraded BioScrip, Inc. (NASDAQ:BIOS) on Tuesday, August 11 to “Buy” rating. The rating was initiated by Lake Street with “Buy” on Tuesday, January 3. The firm has “Buy” rating given on Thursday, November 2 by SunTrust. Jefferies maintained the shares of BIOS in report on Thursday, June 8 with “Buy” rating. The firm earned “Buy” rating on Wednesday, August 9 by Jefferies. The stock of BioScrip, Inc. (NASDAQ:BIOS) earned “Buy” rating by Dougherty & Company on Wednesday, August 12. The rating was upgraded by SunTrust on Thursday, August 10 to “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>